Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Boehringer Ingelheim
AstraZeneca
Merck
Medtronic

Last Updated: January 17, 2022

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OMEPRAZOLE MAGNESIUM

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Omeprazole Magnesium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00206440 ↗ Nexium Study To Suppress Nausea During Chemotherapy Terminated AstraZeneca Phase 3 2005-08-01 This study will look at a drug called esomeprazole, the newest PPI, as a way to further reduce the amount of nausea and vomiting seen in breast cancer patients receiving adriamycin or epirubicin chemotherapy. Esomeprazole may help protect the gut lining from the stomach acid and thus lessen the nausea and vomiting. If patients have less stomach sickness, they may be able to enjoy their daily routines much more while they are getting chemotherapy.
NCT00206440 ↗ Nexium Study To Suppress Nausea During Chemotherapy Terminated Baylor Breast Care Center Phase 3 2005-08-01 This study will look at a drug called esomeprazole, the newest PPI, as a way to further reduce the amount of nausea and vomiting seen in breast cancer patients receiving adriamycin or epirubicin chemotherapy. Esomeprazole may help protect the gut lining from the stomach acid and thus lessen the nausea and vomiting. If patients have less stomach sickness, they may be able to enjoy their daily routines much more while they are getting chemotherapy.
NCT00674115 ↗ A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (CL2007-17 )(P07813)(COMPLETED) Completed Bausch Health Americas, Inc. Phase 3 2008-04-01 Open-label randomized crossover design studies. 60 participants will be evaluated on Day 1 to compare effects on stomach acid; 30 participants will continue treatment for 7 days and will have repeat evaluations at Day 7. The other 30 participants will receive a single administration of sodium bicarbonate.
NCT00674115 ↗ A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (CL2007-17 )(P07813)(COMPLETED) Completed Valeant Pharmaceuticals International, Inc. Phase 3 2008-04-01 Open-label randomized crossover design studies. 60 participants will be evaluated on Day 1 to compare effects on stomach acid; 30 participants will continue treatment for 7 days and will have repeat evaluations at Day 7. The other 30 participants will receive a single administration of sodium bicarbonate.
NCT00674115 ↗ A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (CL2007-17 )(P07813)(COMPLETED) Completed Bayer Phase 3 2008-04-01 Open-label randomized crossover design studies. 60 participants will be evaluated on Day 1 to compare effects on stomach acid; 30 participants will continue treatment for 7 days and will have repeat evaluations at Day 7. The other 30 participants will receive a single administration of sodium bicarbonate.
NCT00693225 ↗ Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study Completed Bausch Health Americas, Inc. Phase 4 2008-01-01 The purpose of this study was to determine the effect of morning versus bedtime administration of omeprazole/sodium bicarbonate (Zegerid) on endoscopic healing for patients with moderate or severe reflux esophagitis. Our hypothesis was that bedtime administration of Zegerid would be superior in healing esophagitis compared to morning administration prior to a meal.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Omeprazole Magnesium

Condition Name

Condition Name for Omeprazole Magnesium
Intervention Trials
Healthy 2
HIV 2
Erosive Esophagitis 1
Gastric Acid 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Omeprazole Magnesium
Intervention Trials
Crush Injuries 2
Nausea 1
Neoplasm Metastasis 1
Heartburn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Omeprazole Magnesium

Trials by Country

Trials by Country for Omeprazole Magnesium
Location Trials
United States 3
Netherlands 2
India 2
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Omeprazole Magnesium
Location Trials
Minnesota 1
Texas 1
Arizona 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Omeprazole Magnesium

Clinical Trial Phase

Clinical Trial Phase for Omeprazole Magnesium
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
Phase 2 1
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Omeprazole Magnesium
Clinical Trial Phase Trials
Completed 8
Unknown status 1
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Omeprazole Magnesium

Sponsor Name

Sponsor Name for Omeprazole Magnesium
Sponsor Trials
Bausch Health Americas, Inc. 2
Valeant Pharmaceuticals International, Inc. 2
Bayer 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Omeprazole Magnesium
Sponsor Trials
Industry 10
Other 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Medtronic
McKesson
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.